Robert B Petersen

List of Publications by Year
in descending order

78 papers	9,735 citations	36203 51 h-index	66788 78 g-index
130 all docs	130 docs citations	130 times ranked	8867 citing authors

#	Article	IF	Citations
1	Characterization of Anchorless Human PrP With Q227X Stop Mutation Linked to Gerstmann-StrÃussler-Scheinker Syndrome In Vivo and In Vitro. Molecular Neurobiology, 2021, 58, 21-33.	1.9	4
2	Emerging physiological and pathological roles of MeCP2 in non-neurological systems. Archives of Biochemistry and Biophysics, 2021, 700, 108768.	1.4	10
3	Muscular G9a Regulates Muscle-Liver-Fat Axis by Musclin Under Overnutrition in Female Mice. Diabetes, 2020, 69, 2642-2654.	0.3	21
4	Multigenerational maternal obesity increases the incidence of HCC in offspring via miR-27a-3p. Journal of Hepatology, 2020, 73, 603-615.	1.8	59
5	Lmo4â€resistin signaling contributes to adipose tissueâ€liver crosstalk upon weight cycling. FASEB Journal, 2020, 34, 4732-4748.	0.2	14
6	Early preclinical detection of prions in the skin of prion-infected animals. Nature Communications, 2019, 10, 247.	5.8	46
7	In Vitro Seeding Activity of Glycoform-Deficient Prions from Variably Protease-Sensitive Prionopathy and Familial CJD Associated with PrPV180I Mutation. Molecular Neurobiology, 2019, 56, 5456-5469.	1.9	7
8	Prion seeding activity and infectivity in skin samples from patients with sporadic Creutzfeldt-Jakob disease. Science Translational Medicine, 2017, 9, .	5.8	103
9	Quiescin-sulfhydryl oxidase inhibits prion formation in vitro. Aging, 2016, 8, 3419-3429.	1.4	2
10	T-Tau and P-Tau in Brain and Blood from Natural and Experimental Prion Diseases. PLoS ONE, 2015, 10, e0143103.	1.1	8
11	Impaired Neutrophil Function in 24p3 Null Mice Contributes to Enhanced Susceptibility to Bacterial Infections. Journal of Immunology, 2013, 190, 4692-4706.	0.4	58
12	Recombinant Human Prion Protein Inhibits Prion Propagation in vitro. Scientific Reports, 2013, 3, 2911.	1.6	27
13	Influence of Mabs on PrPSc Formation Using In Vitro and Cell-Free Systems. PLoS ONE, 2012, 7, e41626.	1.1	3
14	Amyloid-Î²42 Interacts Mainly with Insoluble Prion Protein in the Alzheimer Brain. Journal of Biological Chemistry, 2011, 286, 15095-15105.	1.6	75
15	Mitochondria: A therapeutic target in neurodegeneration. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 212-220.	1.8	244
16	Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. Neurochemistry International, 2009, 54, 84-88.	1.9	125
17	The Neuronal Expression of MYC Causes a Neurodegenerative Phenotype in a Novel Transgenic Mouse. American Journal of Pathology, 2009, 174, 891-897.	1.9	82
18	Prion Protein (PrP) Knock-Out Mice Show Altered Iron Metabolism: A Functional Role for PrP in Iron Uptake and Transport. PLoS ONE, 2009, 4, e6115.	1.1	85

#	Article	IF	Citations
19	Evidence of DNA damage in Alzheimer disease: phosphorylation of histone H2AX in astrocytes. Age, 2008, 30, 209-215.	3.0	133
20	Ligand binding promotes prion protein aggregation â€“ role of the octapeptide repeats. FEBS Journal, 2008, 275, 5564-5575.	2.2	24
21	Antigenâ€“antibody dissociation in Alzheimer disease: a novel approach to diagnosis. Journal of Neurochemistry, 2008, 106, 1350-1356.	2.1	47
22	Bovine Spongiform Encephalopathy and Aquaculture. Journal of Alzheimer's Disease, 2008, 17, 277-279.	1.2	5
23	Signal Transduction Cascades Associated with Oxidative Stress in Alzheimer's Disease. Journal of Alzheimer's Disease, 2007, 11, 143-152.	1.2	95
24	Neuronal cell cycle re-entry mediates Alzheimer disease-type changes. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2007, 1772, 467-472.	1.8	147
25	The Parkinsonâ€™s disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase thatstimulates kinase activity. Experimental Cell Research, 2007, 313, 3658-3670.	1.2	192
26	Chronic Wasting Disease of Elk and Deer and Creutzfeldt-Jakob Disease. Journal of Biological Chemistry, 2006, 281, 4199-4206.	1.6	37
27	Passage of chronic wasting disease prion into transgenic mice expressing Rocky Mountain elk (Cervus) Tj ETQq1 1 0.784314 rgBT /Ov	1.3	66
28	Redox metals and oxidative abnormalities in human prion diseases. Acta Neuropathologica, 2005, 110, 232-238.	3.9	52
29	Characterization of the F198S prion protein mutation: Enhanced glycosylation and defective refolding. Journal of Alzheimer's Disease, 2005, 7, 159-171.	1.2	18
30	Chronic Wasting Disease of Elk: Transmissibility to Humans Examined by Transgenic Mouse Models. Journal of Neuroscience, 2005, 25, 7944-7949.	1.7	235
31	Neuroprotective properties of Bcl-w in Alzheimer disease. Journal of Neurochemistry, 2004, 89, 1233-1240.	2.1	54
32	Oxidative Stress and Redox-Active Iron in Alzheimer's Disease. Annals of the New York Academy of Sciences, 2004, 1012, 179-182.	1.8	179
33	Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimerâ€™s disease. Acta Neuropathologica, 2004, 107, 365-371.	3.9	60
34	Alzheimer disease: Evidence for a central pathogenic role of iron-mediated reactive oxygen species. Journal of Alzheimer's Disease, 2004, 6, 165-169.	1.2	100
35	A metabolic basis for Alzheimer disease. Neurochemical Research, 2003, 28, 1549-1552.	1.6	51
36	Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. BioMetals, 2003, 16, 77-81.	1.8	94

#	Article	IF	Citations
37	Oxidative Stress and Neuronal Adaptation in Alzheimer Disease: The Role of SAPK Pathways. Antioxidants and Redox Signaling, 2003, 5, 571-576.	2.5	67
38	Will Preventing Protein Aggregates Live Up to Its Promise as Prophylaxis Against Neurodegenerative Diseases?. Brain Pathology, 2003, 13, 630-638.	2.1	24
39	Cell-surface prion protein interacts with glycosaminoglycans. Biochemical Journal, 2002, 368, 81-90.	1.7	127
40	Intercellular Transfer of the Cellular Prion Protein. Journal of Biological Chemistry, 2002, 277, 47671-47678.	1.6	95
41	You can take the Genome out of the Organism, but can you take the Organism out of the Environment?. Journal of Alzheimer's Disease, 2002, 4, 167-168.	1.2	0
42	Spontaneous mutations in the prion protein gene causing transmissible spongiform encephalopathy. Annals of Neurology, 2002, 52, 355-359.	2.8	37
43	Induction of HO-1 and NOS in Doppel-Expressing Mice Devoid of PrP: Implications for Doppel Function. Molecular and Cellular Neurosciences, 2001, 17, 768-775.	1.0	62
44	Increased levels of oxidative stress markers detected in the brains of mice devoid of prion protein. Journal of Neurochemistry, 2001, 76, 565-572.	2.1	163
45	The Expression and Potential Function of Cellular Prion Protein in Human Lymphocytes. Cellular Immunology, 2001, 207, 49-58.	1.4	93
46	Differential expression of cellular prion protein in mouse brain as detected with multiple anti-PrP monoclonal antibodies. Brain Research, 2001, 896, 118-129.	1.1	57
47	Oxidative Damage Is the Earliest Event in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2001, 60, 759-767.	0.9	1,670
48	Novel Differences between Two Human Prion Strains Revealed by Two-dimensional Gel Electrophoresis. Journal of Biological Chemistry, 2001, 276, 37284-37288.	1.6	53
49	Normal Cellular Prior Protein Is Preferentially Expressed on Subpopulations of Murine Hemopoietic Cells. Journal of Immunology, 2001, 166, 3733-3742.	0.4	58
50	Mitochondrial Abnormalities in Alzheimer's Disease. Journal of Neuroscience, 2001, 21, 3017-3023.	1.7	1,179
51	Altered cell-matrix associated ADAM proteins in Alzheimer disease. Journal of Neuroscience Research, 2000, 59, 680-684.	1.3	18
52	The Thr183Ala Mutation, Not the Loss of the First Glycosylation Site, Alters the Physical Properties of the Prion Protein. Journal of Alzheimer's Disease, 2000, 2, 27-35.	1.2	42
53	Overexpression of Heme Oxygenase in Neuronal Cells, the Possible Interaction with Tau. Journal of Biological Chemistry, 2000, 275, 5395-5399.	1.6	171
54	Protein Disulfide Isomerase in Alzheimer Disease. Antioxidants and Redox Signaling, 2000, 2, 485-489.	2.5	53

#	Article	IF	Citations
55	Prion Disease: A Loss of Antioxidant Function?. Biochemical and Biophysical Research Communications, 2000, 275, 249-252.	1.0	92
56	Effect of the E200K Mutation on Prion Protein Metabolism. American Journal of Pathology, 2000, 157, 613-622.	1.9	74
57	Expression and Structural Characterization of the Recombinant Human Doppel Protein,. Biochemistry, 2000, 39, 13575-13583.	1.2	38
58	Proteasomal Degradation and N-terminal Protease Resistance of the Codon 145 Mutant Prion Protein. Journal of Biological Chemistry, 1999, 274, 23396-23404.	1.6	153
59	Prion Protein Glycosylation Is Sensitive to Redox Change. Journal of Biological Chemistry, 1999, 274, 34846-34850.	1.6	63
60	Antemortem diagnosis of variant Creutzfeldt-Jakob disease. Lancet, The, 1999, 353, 163-164.	6.3	5
61	Familial Mutations and the Thermodynamic Stability of the Recombinant Human Prion Protein. Journal of Biological Chemistry, 1998, 273, 31048-31052.	1.6	176
62	Molecular Pathology of Fatal Familial Insomnia. Brain Pathology, 1998, 8, 539-548.	2.1	98
63	pH-dependent Stability and Conformation of the Recombinant Human Prion Protein PrP(90â€“231). Journal of Biological Chemistry, 1997, 272, 27517-27520.	1.6	239
64	FLP-mediated DNA mobilization to specific target sites in Drosophila chromosomes. Nucleic Acids Research, 1997, 25, 3665-3671.	6.5	111
65	Prion Protein Aggregation Reverted by Low Temperature in Transfected Cells Carrying a Prion Protein Gene Mutation. Journal of Biological Chemistry, 1997, 272, 28461-28470.	1.6	86
66	Molecular assessment of the potential transmissibilities of BSE and scrapie to humans. Nature, 1997, 388, 285-288.	13.7	259
67	New topics in familial prion diseases. Seminars in Virology, 1996, 7, 181-187.	4.1	3
68	Molecular basis of phenotypic variability in sporadc creudeldt-jakob disease. Annals of Neurology, 1996, 39, 767-778.	2.8	819
69	Effect of the D178N Mutation and the Codon 129 Polymorphism on the Metabolism of the Prion Protein. Journal of Biological Chemistry, 1996, 271, 12661-12668.	1.6	125
70	Fatal Familial Insomnia and Familial Creutzfeldtâ€Jakob Disease: Clinical, Pathological and Molecular Features. Brain Pathology, 1995, 5, 43-51.	2.1	192
71	A FAMILY WITH OCULOLEPTOMENINGEAL AMYLOIDOSIS AND DEMENTIA HAS A MUTATION IN THE TRANSTHYRETIN GENE. Journal of Neuropathology and Experimental Neurology, 1995, 54, 413.	0.9	8
72	Regional distribution of protease-resistant prion protein in fatal familial insomnia. Annals of Neurology, 1995, 38, 21-29.	2.8	165

#	Article	IF	Citations
73	A novel mechanism of phenotypic heterogeneity demonstrated by the effect of a polymorphism on a pathogenic mutation in the PRNP (prion protein gene). Molecular Neurobiology, 1994, 8, 99-103.	1.9	9
74	Abnormal eye movements in Creutzfeldt-Jakob disease. Annals of Neurology, 1993, 34, 192-197.	2.8	78
75	RNA metabolism: strategies for regulation in the heat shock response. Trends in Genetics, 1990, 6, 223-227.	2.9	142
76	Selective Translation and Degradation of Heat-Shock Messenger RNAs in Drosophila. Enzyme, 1990, 44, 147-166.	0.7	89
77	The Drosophila hsp70 message is rapidly degraded at normal temperatures and stabilized by heat shock. Gene, 1988, 72, 161-168.	1.0	104
78	Synthesis in vitro of a seven amino acid peptide encoded in the leader RNA of Rous sarcoma virus. Journal of Molecular Biology, 1986, 190, 45-57.	2.0	75